Carmen Rodriguez-Cueto
Overview
Explore the profile of Carmen Rodriguez-Cueto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
354
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gomez-Canas M, Rodriguez-Cueto C, Fernandez-Ruiz J, de Lago E
Methods Mol Biol
. 2025 Mar;
2899:339-366.
PMID: 40067634
This chapter aims to elucidate an example of the drug development process for a G protein-coupled receptor (GPCR), focusing specifically on the cannabinoid receptors CB and CB. Various techniques can...
2.
Silva-Llanes I, Martin-Baquero R, Berrojo-Armisen A, Rodriguez-Cueto C, Fernandez-Ruiz J, de Lago E, et al.
Antioxidants (Basel)
. 2024 Sep;
13(9).
PMID: 39334731
Frontotemporal dementia (FTD) causes progressive neurodegeneration in the frontal and temporal lobes, leading to behavioral, cognitive, and language impairments. With no effective treatment available, exploring new therapeutic approaches is critical....
3.
Gonzalo-Consuegra C, Santos-Garcia I, Garcia-Toscano L, Martin-Baquero R, Rodriguez-Cueto C, Wittwer M, et al.
Biomed Pharmacother
. 2024 Mar;
174:116473.
PMID: 38522237
Background: The elevation of endocannabinoid levels through inhibiting their degradation afforded neuroprotection in CaMKIIα-TDP-43 mice, a conditional transgenic model of frontotemporal dementia. However, which cannabinoid receptors are mediating these benefits...
4.
Santos-Garcia I, Rodriguez-Cueto C, Villegas P, Piscitelli F, Lauritano A, Shen C, et al.
J Neuroinflammation
. 2023 May;
20(1):108.
PMID: 37149645
Background: Frontotemporal dementia (FTD) is a heterogeneous group of early onset and progressive neurodegenerative disorders, characterized by degeneration in the frontal and temporal lobes, which causes deterioration in cognition, personality,...
5.
Gomez-Canas M, Morales P, Satta V, Rodriguez-Cueto C, Garcia C, Sagredo O
Front Neurosci
. 2023 Jan;
16:1108101.
PMID: 36605545
No abstract available.
6.
Gomez-Canas M, Rodriguez-Cueto C, Satta V, Hernandez-Fisac I, Navarro E, Fernandez-Ruiz J
Methods Mol Biol
. 2022 Sep;
2576:67-94.
PMID: 36152178
Cannabis plant has been used from ancient times with therapeutic purposes for treating human pathologies, but the identification of the cellular and molecular mechanisms underlying the therapeutic properties of the...
7.
Burgaz S, Garcia C, Gonzalo-Consuegra C, Gomez-Almeria M, Ruiz-Pino F, Unciti J, et al.
Molecules
. 2021 Dec;
26(24).
PMID: 34946726
Cannabinoids act as pleiotropic compounds exerting, among others, a broad-spectrum of neuroprotective effects. These effects have been investigated in the last years in different preclinical models of neurodegeneration, with the...
8.
Gomez-Almeria M, Burgaz S, Costas-Insua C, Rodriguez-Cueto C, Santos-Garcia I, Rodriguez-Crespo I, et al.
Int J Mol Sci
. 2021 Nov;
22(22).
PMID: 34830414
In the present study, we investigated the involvement of the chaperone protein BiP (also known as GRP78 or Hspa5), a master regulator of intracellular proteostasis, in two mouse models of...
9.
Rodriguez-Cueto C, Gomez-Almeria M, Toscano L, Romero J, Hillard C, de Lago E, et al.
Brain Pathol
. 2021 May;
31(6):e12972.
PMID: 33983653
The activation of the cannabinoid receptor type-2 (CB ) afforded neuroprotection in amyotrophic lateral sclerosis (ALS) models. The objective of this study was to further investigate the relevance of the...
10.
Fernandez-Ruiz J, de Lago E, Rodriguez-Cueto C, Moro M
Br J Pharmacol
. 2021 Feb;
178(6):1253-1256.
PMID: 33638898
No abstract available.